Knopp posts data of KB-3061 working on KCNQ2 Epileptic Encephalopathy
Category: #health  By Mateen Dalal  Date: 2019-09-18
  • share
  • Twitter
  • Facebook
  • LinkedIn

Knopp posts data of KB-3061 working on KCNQ2 Epileptic Encephalopathy

KCNQ2 epileptic encephalopathies is a serious type of neonatal epileptic condition which manifests in newborn children during the first week if their lives. This disease is being addressed by various pharmaceutical companies across the globe trying their best to find an effective as well as cost efficient drug for treatment.

Knopp Biosciences LLC, a drug discovery and development firm specializing in researching therapies to treat neurological disorders, recently reported outcomes of preclinical experiments showcasing that KB-3061, a leading molecule in the ion channel platform of company, restored Kv7 potassium channels’ function in cells that were engineered to express the gene variants which cause KCNQ2 epileptic encephalopathy, commonly referred to as KCNQ2-EE, a rare neonatal disease.

The Chief Executive Officer of Knopp, Michael Bozik, M.D., presented the data at Epilepsy Precision Medicine Conference which was conducted between Sept. 16-17 in Washington. D.C. Bozik’s presentation included preclinical observations from experiments that took place in collaboration with the Associate Professor of Neurosciences, Neurology and Molecular & Human Genetics in the Baylor College of Medicine, Edward C. Cooper, M.D., Ph.D.

These experiments expand the pharmacology earlier reported for KB-3061, including the invitro nanomolar activity of molecule in wild type Kv7.2 or Kv7.3 potassium channels.

Dr. Bozik further added that cells that are transfected to stimulate three missense mutations that are highly-recurrent to the KCNQ2 gene showcased strong function suppression, as measured by significantly decreased potassium current in the mutated Kv7.2 channels.

When it was treated with KB-3061, the mutated channels functioning was fully restored, they were producing regular Kv7.2 channel current density.

Knopp is enhancing the KB-3061 development as potential precision medicine to treat KCNQ2-EE, a neonatal, genetically-defined disease that is linked with seizures starting after birth as well as profound developmental delay. This disease happens due to dominant-negative mutations present in KCNQ2 gene, which creates a potassium channel, Kv7.2, which is crucial for to early brain development.

Dr. Bozik stated that the data generated in cooperation with Dr. Cooper supports the approach of precision medical to KCNQ2-EE. Bozik added that the outcomes suggest that restoring back suppressed channel activity of Kv7.2 may improve the dysfunction caused due to the KCNQ2 gene mutations.

Earlier in May, Knopp presented positive preclinical outcomes of Neonatal Epilepsy Drug candidate for KCNQ2-neonatal epileptic encephalopathy at the Antiepileptic Drug and Device Trials XV Conference.

 

Source credit: https://knoppbio.com/news-and-events/knopp-biosciences-reports-data-demonstrating-restoration-of-function-by-kb-3061-in-cellular-model-of-gene-variants-causing-kcnq2-epileptic-encephalopathy

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Telenor to sell stake in Myanmar's Wave Money for $53 Mn to Yoma
Telenor to sell stake in Myanmar's Wave Money for $53 Mn to Yoma
By Mateen Dalal

Telenor Group, an international provider of tele, data and media communication services, has reportedly agreed to sell its 51% stake in Myanmar's Wave Money, a provider of digital payment service, for $53 million to Yoma MFS Holdings, a subsidiar...

Alkem to launch state-of-the-art technology to treat DFU in India
Alkem to launch state-of-the-art technology to treat DFU in India
By Mateen Dalal

Alkem Laboratories Ltd. (Alkem), an Indian multinational pharmaceutical company, has reportedly launched a unique patented technology for the treatment of Diabetic Foot Ulcer (DFU) in India. The solution would be based on an innovative technology of...

Bank of America unveils new drive-thru ATM; shuts another in Bethlehem
Bank of America unveils new drive-thru ATM; shuts another in Bethlehem
By Mateen Dalal

According to Andy Aldridge, Bank of America Spokesperson, the financial institutiThe Bank of America Corporation, an American multinational investment bank and financial services, has now opened up a new place for clients in North Bethlehem who are l...